COOPERVISION &lt;EYE> DELAYS ANNUAL MEETING CooperVision delayed annual meeting June 22 14 board review recapitalization options meeting. CooperVision today reported quarter net income 64.6 mln dlrs, 175.2 mln dlr pretax gain sale ophthalmic business Johnson Johnson &lt;JNJ> 260 mln dlrs cash 17.9 mln dlr posttax charge debt repurchase. Sales 94.4 mln dlrs. year earlier earned 7,300,000 dlrs 120,000 dlr loss discontinued operations, sales 85.4 mln dlrs. company aggressive program investment spending maintain increase market shares core businesses accelerate sales growth year hold back increases operating income future. CooperVision "Furthermore, entire net cash proceeds recent sales businesses employed reduce indebtedness, make strategic acquisitions and/or employed relation recapitalization company, recovery net income held back loss, tax income, (ophthalmic) pharmaceutical business sold Johnson Johnson."